Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500772 · ClinicalTrials.gov registry record · Phase 3
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
A Phase 3 study, sponsored by Debiopharm International.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT01500772 is a Phase 3 study that was terminated before completion, run by Debiopharm International. The registered enrollment target is 6 participants.
The verdict
NCT01500772, a Phase 3 study, was terminated before completion, sponsored by Debiopharm International.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin (RBV) patients with chronic hepatitis C (HCV) genotype 1 who failed prior treatment with a protease inhibitor (PI).
Interventions
- DRUG Ribavirin
- DRUG Peginterferon alfa-2a
- DRUG Alisporivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01500772
The ClinicalTrials.gov registry entry for NCT01500772 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01500772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01500772 about?
NCT01500772 is a clinical study titled "Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C". This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin (RBV) patients with chronic hepatitis C (HCV) genotype 1 who failed prior treatment with a protease inhibitor (PI).
What is the current status of trial NCT01500772?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2012-03. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01500772?
The interventions under investigation include: Ribavirin (DRUG), Peginterferon alfa-2a (DRUG), Alisporivir (DRUG).
Who is sponsoring clinical trial NCT01500772?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.